News Releases

NEW YORK --(BUSINESS WIRE)--Apr. 1, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and

Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 Company to host conference call and webcast today, March 25 , at 4:30 pm ET NEW YORK , March 25, 2021

NEW YORK & CHICAGO --(BUSINESS WIRE)--Mar. 23, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, and EVERSANA™ , the pioneer of next-generation

Company to host an investor conference call and webcast at 4:30pm ET on that day NEW YORK , March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc.  (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™)

NEW YORK --(BUSINESS WIRE)--Mar. 17, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the publication of “ Mydriasis with micro-array

NEW YORK , March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will participate in

PDUFA Date Expected 4Q 2021 NEW YORK --(BUSINESS WIRE)--Mar. 2, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S.

The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET NEW YORK , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a

Presentation Focuses on the Challenges and Biases Facing Presbyopia Patients, and Potential Benefits of Treatment Delivered with Eyenovia’s Novel Optejet® Dispenser NEW YORK --(BUSINESS WIRE)--Jan. 26, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company

NEW YORK , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, will